B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 9428-9433

  Zhou, Yi ^a   Xu, Yun ^a   Chen, Lujun ^a   Xu, Bin ^a   Wu, Changping ^a   Jiang, Jingting ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

B7 H6; Immunohistochemistry; Ovarian cancer; Prognosis; Tissue microarray

Indexed keywords

B7 ANTIGEN; B7-H6 ANTIGEN, HUMAN;

DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

B7 ANTIGENS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; SURVIVAL RATE;

EID: 85013015696     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015 CA Cancer J Clin 2015; 65: 5-29.
2. Barnett B, Kryczek I, Cheng P, Zou W and Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-377.
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
4. Goyne HE and Cannon MJ. Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front Immunol 2013; 4: 382.
5. Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V and Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013; 11: 147.
6. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, WinterhoffB, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB and Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One 2013; 8: e53903.
7. Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J and Zhang X. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res 2011; 50: 269-275.
8. Seliger B and Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012; 61: 1327-1341.
9. Zou W and Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477.
10. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T and Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 3360-3365.
11. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J and Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-1112.
12. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G and Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900-8905.
13. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL and Diamandis EP. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 2007; 106: 334-341.
14. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E and Levin SD. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495-1503.
15. Chen XJ, Shen J, Zhang GB and Chen WC. B7-H6 protein expression has no prognostic significance in human gastric carcinoma. Pathol Oncol Res 2014; 20: 203-207.
16. Zhang X, Zhang G, Qin Y, Bai R and Huang J. B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol 2014; 7: 6936-6942.
17. Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J and Wu C. B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol 2014; 7: 6015-6023.
18. Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, Shan BE, Lu BF and Zhang XG. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011; 60: 1047-1055.
19. Chen L, Di D, Luo G, Zheng L, Tan Y, Zhang X and Xu N. Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res 2010; 30: 4363-4368.
20. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-2716.
21. Jung K and Choi I. Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Netw 2013; 13: 184-193.
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
23. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM. Safety and activity of anti-PD-L1 antibnody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
24. Li G, Yang Q, Zhu Y, Wang HR, Chen X, Zhang X and Lu B. T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells. PLoS One 2013; 8: e67401.
25. Fiegler N, Textor S, Arnold A, Rolle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M and Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013; 122: 684-693.
26. Wu MR, Zhang T, DeMars LR and Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther 2015; 22: 675-684.
27. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vely F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D and Zitvogel L. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7: 283ra255.